Media
Press Releases
![](https://www.spinogenix.com/wp-content/uploads/2024/04/Spinogenix-pr.png)
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome
![](https://www.spinogenix.com/wp-content/uploads/2023/11/2Group-3362.png)
Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease
![](https://www.spinogenix.com/wp-content/uploads/2024/05/FDA-cleared-blue.png)
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS
![](https://www.spinogenix.com/wp-content/uploads/2024/05/FDA2-blue.png)
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
![](https://www.spinogenix.com/wp-content/uploads/2024/04/Spinogenix-pr.png)
Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
![](https://www.spinogenix.com/wp-content/uploads/2023/11/Group-3362.png)
Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/Group-3363.png)
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
![](https://www.spinogenix.com/wp-content/uploads/2023/11/2Group-3362.png)
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
![](https://www.spinogenix.com/wp-content/uploads/2023/09/fda-logo.png)
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
![](https://www.spinogenix.com/wp-content/uploads/2023/11/Group-3362.png)
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)
![](https://www.spinogenix.com/wp-content/uploads/2023/11/test-gold-ball.png)